Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

Af­ter snag­ging IND ap­proval for its off-the-shelf virus-spe­cif­ic T cell Covid-19 ther­a­py, AlloVir is now rac­ing to­ward a proof-of-con­cept study.

The can­di­date, ALVR109,  is de­signed to halt the pro­gres­sion of Covid-19 by de­stroy­ing SARS-CoV-2-in­fect­ed cells.

In March, AlloVir ex­pand­ed its part­ner­ship with the Bay­lor Col­lege of Med­i­cine to de­vel­op treat­ments that re­store T-cell im­mu­ni­ty in im­mune-com­pro­mised pa­tients. In ad­di­tion to Covid-19, the pro­gram pur­sues SARS clas­sic, MERS and four oth­er coro­n­avirus­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.